Study S000465

A Multicentre, Single-arm, Retrospective Study Investigating Glycaemic Control in GLP-1 Naive Participants With Type 2 Diabetes Who Initiated Once-weekly Semaglutide (OZEMPIC) in a Real World Setting in North Macedonia

ClinicalTrials.gov record

Registration

Registration: NCT05468632
Acronym: MIRAGE
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 314
Start: 2022-07-05
Primary completion: 2022-07-31
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1273-4429

Registered primary outcomes

Change in glycated haemoglobin (HbA1c) [From baseline (week 0) to end of follow-up (week 30+- 4 weeks)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.